tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Fidia S.p.A. Approves 2024 Financial Statements Amidst Strategic Restructuring

Story Highlights
Fidia S.p.A. Approves 2024 Financial Statements Amidst Strategic Restructuring

Elevate Your Investing Strategy:

The latest announcement is out from Fidia Spa ( (IT:FDA) ).

Fidia S.p.A. held its Ordinary Shareholders’ Meeting, approving the 2024 financial statements which reported a significant loss of Euro 9,421 thousand, a substantial increase from the previous year. The company also decided to reduce its share capital to cover accumulated losses. Despite the challenging financial year, Fidia remains optimistic about its future, with a promising order portfolio and a strategic plan aimed at returning to positive EBITDA by 2025, supported by favorable industry forecasts.

More about Fidia Spa

Fidia S.p.A. is an international leader in the field of numerical controls and specializes in the design, production, and marketing of high-performance integrated milling systems. The company is publicly traded on Euronext Milan and focuses on providing advanced technological solutions in the industrial machinery sector.

YTD Price Performance: -78.26%

Average Trading Volume: 3,970,081

Technical Sentiment Signal: Strong Sell

Current Market Cap: €3.14M

For an in-depth examination of FDA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1